aTyr Pharma, Inc. Total Assets
aTyr Pharma, Inc. total assets. Based on the latest financial reports, aTyr Pharma, Inc. (ATYR) holds total assets worth $94.16 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see aTyr Pharma, Inc. (ATYR) total market value for the company's overall valuation and market capitalisation.
Total Assets of aTyr Pharma, Inc. (2012–2025)
Total assets of aTyr Pharma, Inc. from 2012 to 2025. This chart illustrates how aTyr Pharma, Inc.'s total assets have evolved over time, based on quarterly financial data. See ATYR stock price for real-time trading data and today's change.
aTyr Pharma, Inc. - Asset Composition Analysis
aTyr Pharma, Inc. Total Assets Breakdown (December 2025)
aTyr Pharma, Inc. total assets breakdown as of December 2025. aTyr Pharma, Inc.'s total assets of $94.16 Million consist of 85.2% current assets and 14.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.4% |
| Accounts Receivable | $873.00K | 0.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how aTyr Pharma, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore aTyr Pharma, Inc. short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: aTyr Pharma, Inc.'s current assets represent 85.2% of total assets in 2025, an increase from 60.2% in 2012.
- Cash Position: Cash and equivalents constituted 11.4% of total assets in 2025, down from 49.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 0.9% of total assets.
aTyr Pharma, Inc. Competitors by Total Assets
Key competitors of aTyr Pharma, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
aTyr Pharma, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.30 | 5.48 | 11.71 |
| Quick Ratio | 5.30 | 5.48 | 11.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $65.09 Million | $66.99 Million | $47.68 Million |
aTyr Pharma, Inc. - Advanced Valuation Insights
This section examines the relationship between aTyr Pharma, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.38 |
| Latest Market Cap to Assets Ratio | 0.99 |
| Asset Growth Rate (YoY) | -2.8% |
| Total Assets | $94.16 Million |
| Market Capitalization | $92.79 Million USD |
Valuation Analysis
Near Book Valuation: The market values aTyr Pharma, Inc.'s assets close to their book value (0.99x), suggesting investors view the company's assets at approximately fair value.
Slight Asset Contraction: aTyr Pharma, Inc.'s assets decreased by 2.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for aTyr Pharma, Inc. (2012–2025)
The table below shows the annual total assets of aTyr Pharma, Inc. from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $94.16 Million | -2.75% |
| 2024-12-31 | $96.83 Million | -19.75% |
| 2023-12-31 | $120.65 Million | +25.96% |
| 2022-12-31 | $95.79 Million | -17.09% |
| 2021-12-31 | $115.54 Million | +198.34% |
| 2020-12-31 | $38.73 Million | +7.01% |
| 2019-12-31 | $36.19 Million | -31.39% |
| 2018-12-31 | $52.75 Million | -40.97% |
| 2017-12-31 | $89.36 Million | +10.97% |
| 2016-12-31 | $80.52 Million | -37.90% |
| 2015-12-31 | $129.68 Million | +528.15% |
| 2014-12-31 | $20.64 Million | -48.11% |
| 2013-12-31 | $39.79 Million | +432.90% |
| 2012-12-31 | $7.47 Million | -- |
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinica… Read more